by Stacey Hawkins | Feb 19, 2020 | Immunotherapies
Chimeric antigen receptor T-cells (CAR-Ts), reviewed last week, are a powerful new weapon for oncologists to use in their fight against cancer. These engineered T-cells are designed to home in on and kill malignant cells, and have proven highly effective at treating... 
by Stacey Hawkins | Apr 21, 2020 | Oncology
Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of treatment, while inroads against... 
by Stacey Hawkins | Mar 18, 2020 | Autoimmune and immunology
The immune system. Now more than ever we are recognizing its importance to our health. But what the heck is it? In short, the immune system is a complicated network of organs, cells, and signaling molecules. Without this guardian, we fall prey to dangerous pathogens... 
by Stacey Hawkins | Feb 10, 2020 | Immunotherapies
The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—Kymriah (Novartis; Basel, Switzerland) and Yescarta—(Gilead; Foster City, CA) were approved in 2017, and remain one of the hottest immunotherapies on the market today. They work by... 
by Stacey Hawkins | Sep 11, 2019 | Gene Therapy/Genome Editing
Gene Therapy Targets AIDS For many years, a diagnosis of acquired immunodeficiency syndrome (AIDS) was a death sentence. It seemed unthinkable in the 1980s, but the medical community now largely treats the disease as a chronic illness. This profound shift arose...
